Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients
| Autor: | Mikkel Andreassen, Gedske Daugaard, Malene Elbaek Vikner, Jesper Krogh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Antineoplastic Agents Hormonal Denmark Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Sex hormone-binding globulin Internal medicine Adrenocortical Carcinoma medicine Humans Adrenocortical carcinoma Endocrine system Mitotane Testosterone Retrospective Studies biology Triglyceride business.industry medicine.disease Adrenal Cortex Neoplasms Discontinuation chemistry 030220 oncology & carcinogenesis biology.protein business medicine.drug Hormone |
| Zdroj: | Clinical Endocrinology. 94:141-149 |
| ISSN: | 1365-2265 0300-0664 |
| DOI: | 10.1111/cen.14345 |
| Popis: | OBJECTIVE Mitotane is used in the treatment of adrenocortical carcinoma (ACC). Metabolic and hormonal side effects of mitotane, the effect of subsequent treatment with statins and hormones and the effects of discontinuation of mitotane were assessed. PATIENTS AND METHODS Fifty patients were included. Lipid profiles, thyroid hormones, sex hormones and adrenal function from first year of mitotane treatment and after cessation were evaluated. RESULTS After 6 months of mitotane treatment total cholesterol increased from (median) 5.1 (IQR 4.3 to 5.8) to 7.4 (6.2-9.0) mmol/L, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text